Lehmensiek Vera, Tan Eva-Maria, Liebau Stefan, Lenk Thomas, Zettlmeisl Heinz, Schwarz Johannes, Storch Alexander
Department of Neurology, University of Ulm, Germany.
Neurochem Int. 2006 Apr;48(5):329-40. doi: 10.1016/j.neuint.2005.11.008. Epub 2006 Jan 6.
6-Hydroxydopamine (6-OHDA) is widely used to produce animal models of Parkinson's disease (PD) by selectively destroying the nigro-striatal dopaminergic systems, but selective toxicity of 6-OHDA towards dopaminergic cells in vitro remains controversial. Mutant (A30P and A53T) alpha-synuclein isoforms cause increased vulnerability of cells towards various toxic insults and enhance dopamine transporter (DAT)-mediated toxicity of the selective dopaminergic neurotoxin and mitochondrial complex I inhibitor MPP(+) in vitro. Here we extend our recent studies on DAT-mediated toxicity to elucidate the mechanisms involved in selective dopaminergic toxicity of 6-OHDA. We studied the cytotoxicity as well as the toxic mechanisms of 6-OHDA in human embryonic kidney HEK-293 cells ectopically co-expressing mutant alpha-synucleins and the human DAT protein. 6-OHDA showed half-maximal toxic concentration (TC(50)) of 88 microM in HEK-hDAT cells without alpha-synuclein expression after 24 h, whereas the TC(50) values significantly decreased to 58 and 39 microM by expression of A30P and A53T alpha-synuclein, respectively. alpha-Synuclein expression did not affect 6-OHDA toxicity in HEK-293 cells not expressing the DAT. Analysis of intracellular parameters of cellular energy metabolism revealed that the co-expression of mutant alpha-synucleins in HEK-hDAT cells accelerates the reduction of intracellular net ATP levels and ATP/ADP ratios induced by 6-OHDA. Uptake function of the DAT was not altered by expression of alpha-synuclein isoforms. Our data suggest a mechanism of 6-OHDA-induced dopaminergic toxicity involving an interaction of mutant alpha-synucleins with the DAT molecule and subsequent acceleration of cellular energy depletion that might be relevant for the pathogenesis of PD.
6-羟基多巴胺(6-OHDA)被广泛用于通过选择性破坏黑质纹状体多巴胺能系统来制备帕金森病(PD)动物模型,但6-OHDA在体外对多巴胺能细胞的选择性毒性仍存在争议。突变型(A30P和A53T)α-突触核蛋白亚型会增加细胞对各种毒性损伤的易感性,并在体外增强多巴胺转运体(DAT)介导的选择性多巴胺能神经毒素和线粒体复合体I抑制剂MPP(+)的毒性。在此,我们扩展了我们最近关于DAT介导毒性的研究,以阐明6-OHDA选择性多巴胺能毒性所涉及的机制。我们研究了6-OHDA在异位共表达突变型α-突触核蛋白和人DAT蛋白的人胚肾HEK-293细胞中的细胞毒性及其毒性机制。在没有α-突触核蛋白表达的HEK-hDAT细胞中,6-OHDA在24小时后显示出半数最大毒性浓度(TC(50))为88μM,而通过表达A30P和A53Tα-突触核蛋白,TC(50)值分别显著降至58μM和39μM。α-突触核蛋白的表达对不表达DAT的HEK-293细胞中的6-OHDA毒性没有影响。对细胞能量代谢的细胞内参数分析表明,HEK-hDAT细胞中突变型α-突触核蛋白的共表达加速了6-OHDA诱导的细胞内净ATP水平和ATP/ADP比值的降低。α-突触核蛋白亚型的表达未改变DAT的摄取功能。我们的数据提示了一种6-OHDA诱导的多巴胺能毒性机制,涉及突变型α-突触核蛋白与DAT分子的相互作用以及随后细胞能量消耗的加速,这可能与PD的发病机制相关。